Biotechnology

HAOHAI BIOTEC

HAOHAI BIOTEC released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue HKD 647.86 M, actual EPS HKD 0.3627

HAOHAI BIOTEC to Release FY2026 Q1 Earnings on April 24 After-Market (BJT)

Hao Hai Biotechnology repurchased approximately 107,200 shares for about HKD 2.4055 million

Howhealing Bio 公布 2025 annual performance with both revenue and profit declining

Haohai Bio-Technology's Subsidiary Obtains Registration Certificate for Intraocular Cross-linked Hyaluronic Acid Gel Product

HAOHAI BIOTEC to Release FY2025 Annual Earnings on March 20, 2026 During-Market (BJT), Forecast Revenue HKD 3.346 B, EPS HKD 2.1931

HAOHAI BIOTEC released FY2025 earnings on February 27 During-Market (BJT), actual revenue HKD 2.674 B (forecast HKD 3.311 B), actual EPS HKD 1.1835 (forecast HKD 2.2162)

HAOHAI BIOTEC released FY2025 Q4 earnings during market hours on February 27, 2026 (BJT), with actual revenue of HKD 638.22 M and EPS of HKD -0.2571

Lu Guolian Plans to Sell Up to 1 Million Shares of Haoke Biotechnology

Howland Biotechnology Acquired Equity in Jiangxi Ruiji Bioengineering Technology Co., Ltd.

Haohai Bio-Pharmaceutical CEO Fined Nearly $2 Million for Insider Trading

Haohai Biotechnology repurchased 17,000 shares for HKD 434,900

Tang Minjie 增持 Haus Health 10,000 股

Hao Hai Bio-Technology repurchased 91,700 shares

Haohai Bio-Technology Acquires 22.26% Equity of Jiangxi Ruiji Biotechnology

Hao Hai Biotechnology and Zhong Xiaoyan Plan to Acquire Equity in Jiangxi Ruiji Bioengineering

Howland Biotech repurchased 42,300 shares for HKD 1,123,800

Haohai Biotechnology repurchased 103,300 shares for HKD 2.7821 million

Hao Hai Biotechnology repurchased 102,100 shares

Haohai Biotechnology repurchased 78,900 shares for HKD 2.1994 million

NEW GONOW RV

ZHONGSHENJIANYE

FAMEGLOW

TJCD

REALWAY CAPITAL

51WORLD

CENTRAL DEV H

ZXZN QI-HOUSE

MEGAIN

EASYHOLD GROUP

Ordinary dividend (cash)

Ex Date: 2026.06.04, Cash dividend 0.6824 HKD

688366

06826

Shanghai Haohai Biological Technology announced that its controlling shareholder, Jiang Wei, has been released on bail in an unrelated insider trading investigation. The company clarified that Jiang does not hold any official position within the firm and that the case does not impact its operations. This follows a previous penalty imposed on Jiang by the China Securities Regulatory Commission for insider trading. The company aims to reassure investors that its governance and regulatory status remain unaffected despite the scrutiny surrounding Jiang.

Tip Ranks

Shanghai Haohai Says Controlling Shareholder Released on Bail in Unrelated Insider Trading Case

513120

520500

Hong Kong Stock Exchange filings show that Wuhan Bin Hui Biological Technology Co., Ltd. - B has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International, China Merchants Securities International, and BOCI Asia Limited as joint sponsors

Wallstreetcn

GF CSI HK Innovative Drugs Industry ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

GREEN FRESH BIO

Hwabao WP CSI Pharmaceuticals ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

WAI CHUN BIOTEC

China Universal CNI HK Connect Innovative Drugs Industry ETF

Bin Hui Biotechnology Submits Listing Application to Hong Kong Stock Exchange

HAOHAI BIOTEC announced its performance for the fiscal year 2025, with revenue of 2.446 billion RMB, a year-on-year decrease of 8.7%. It recorded a net profit of 251 million RMB, a decline of 40.3%, with earnings per share of 1.08 RMB. The final dividend remains at 0.60 RMB

AASTOCKS

"Performance" HAOHAI BIOTEC's annual net profit is 251 million RMB, down 40.3%, with a final dividend of 0.60 RMB

HAOHAI BIOTEC announced its performance preliminary report for the year 2025, achieving total operating revenue of 2.473 billion RMB (same below), a year-on-year decrease of 8.3%. The net profit attributable to the parent company's owners was 251 million RMB, a decline of 40.3%, with earnings per share of 1.08 RMB

According to "Performance," HAOHAI BIOTEC's net profit last year was 251 million RMB, a decline of 40.3%

300896

688363

002612

The National Health Commission reminds that lifestyle beauty institutions, hair salons, nail salons, etc. are not allowed to carry out "light medical beauty" projects. Such projects include non-surgical medical beauty procedures such as injections, phototherapy, and biotechnology, which must be performed by professional medical personnel in institutions with medical beauty service qualifications

IMEIK

Bloomage Biotech

LANCY

National Health Commission: Beauty institutions, hair salons, nail salons, and other lifestyle-related businesses are strictly prohibited from conducting "light medical beauty" projects

Shanghai Haohai Biological Technology Co., Ltd. disclosed that its controlling shareholder, Mr. Jiang Wei, received a penalty from the CSRC for insider trading unrelated to the company. The CSRC confiscated RMB4.71 million and fined RMB14.63 million. The case highlights governance scrutiny of key shareholders, potentially impacting investor perception. The company's stock has a Hold rating with a HK$27.00 price target.

Haohai Biotec Discloses CSRC Penalty Against Controlling Shareholder for Unrelated Insider Trading Case

HAOHAI BIOTEC announced that it will acquire a 19.8% equity stake in Ruiji Biotech from an independent third party. The latter's products are mainly used in the fields of orthopedics and ophthalmology, with a cash consideration of 38.35 million RMB, which will be paid using internal resources

HAOHAI BIOTEC acquires 19.8% of Ruiji Bio for a consideration of 38.35 million RMB

According to the Zhitong Finance APP, HAOHAI BIOTEC announced that on November 3, 2025, the company spent HKD 276,800 to repurchase 10,000 shares, with a repurchase price of HKD 27.64-27.70 per share

Zhitong

On November 3rd, HAOHAI BIOTEC spent HKD 276,800 to repurchase 10,000 shares

According to the Zhitong Finance APP, HAOHAI BIOTEC announced that it will spend HKD 1.2503 million to repurchase 45,500 shares on October 31, 2025

On October 31st, HAOHAI BIOTEC spent HKD 1.2503 million to repurchase 45,500 shares

HAOHAI BIOTEC(06826.HK)